Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Executive Summary

It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.


Related Content

Sarepta Commits To Rapid, Thorough Pivotal Study For DMD Gene Therapy Based On Functional Improvements
Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies
Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Pediatric Rare Disease Voucher Program Faces Expiration
Priority Review Vouchers Appear To Be Dropping In Price
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
Patients Can't Rescue Sarepta's Eteplirsen


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts